ORKA insider disclosures
Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source | Follow |
|---|---|---|---|---|---|---|---|
| Agarwal Arjun Senior Vice President, Finance · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 22761 | 2026-11-12 | 2026-11-13 | 8,542 shares/units | SEC 4 | Follow |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 53426 · The option vests as to 1/4 of the underlying shares on May 7, 2025 and as to 1/48 of the underlying shares monthly from May 7, 2025. | 2026-11-12 | 2026-11-13 | 18,000 shares/units | SEC 4 | Follow |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 0 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.97 to $107.00, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $21,397.00 200 shares/units | SEC 4 | Follow |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 200 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.76 to $106.46, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $265,130.00 2,500 shares/units | SEC 4 | Follow |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 2700 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.76 to $105.75, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $1,133,706.29 10,765 shares/units | SEC 4 | Follow |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 13465 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $103.69 to $104.65, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $212,386.73 2,039 shares/units | SEC 4 | Follow |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 15504 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $102.66 to $103.65, inclusive. | 2026-11-12 | 2026-11-13 | ≈ $134,021.16 1,300 shares/units | SEC 4 | Follow |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 16804 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on August 12, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.62 to $102.61, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6) and (7) to this Form 4. | 2026-11-12 | 2026-11-13 | ≈ $122,107.65 1,196 shares/units | SEC 4 | Follow |
| BALL KRISTINE M Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 18000 | 2026-11-12 | 2026-11-13 | 18,000 shares/units | SEC 4 | Follow |
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Employee Warrant (right to buy) · Derivative security · Direct ownership · Reported balance after transaction: 1503513 · The warrant vests as to 1/4 of the underlying shares on April 3, 2025 and as to 1/48 of the underlying shares monthly from April 3, 2025. | 2026-11-02 | 2026-11-02 | 25,000 shares/units | SEC 4 | Follow |
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 923128 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $98.40 to $98.41, inclusive. | 2026-11-02 | 2026-11-02 | ≈ $29,520.99 300 shares/units | SEC 4 | Follow |
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 923428 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.30 to $98.12, inclusive. | 2026-11-02 | 2026-11-02 | ≈ $73,675.53 756 shares/units | SEC 4 | Follow |
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 924184 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.25 to $97.24, inclusive. | 2026-11-02 | 2026-11-02 | ≈ $236,146.53 2,442 shares/units | SEC 4 | Follow |
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 926626 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.25 to $96.23, inclusive. | 2026-11-02 | 2026-11-02 | ≈ $1,437,987.41 15,036 shares/units | SEC 4 | Follow |
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | SellFiling detailsSEC transaction code S Common Stock · Direct ownership · Reported balance after transaction: 941662 · SEC code covers open-market or private transactions · These sales were effected pursuant to a Rule 10b5-1 trading plan entered into on May 14, 2026. · The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.25 to $95.24, inclusive. The reporting person undertakes to provide to Oruka Therapeutics, Inc., any security holder of Oruka Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5) and (6) to this Form 4. | 2026-11-02 | 2026-11-02 | ≈ $612,794.46 6,466 shares/units | SEC 4 | Follow |
| Klein Lawrence Otto Chief Executive Officer · Director · Oruka Therapeutics, Inc. | ORKA Oruka Therapeutics, Inc. | Exercise or conversionFiling detailsSEC transaction code M Common Stock · Direct ownership · Reported balance after transaction: 948128 | 2026-11-02 | 2026-11-02 | 25,000 shares/units | SEC 4 | Follow |
Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.